141 related articles for article (PubMed ID: 36661708)
21. Current status of diagnosis and treatment of advanced non-small cell lung cancer in China during the COVID-19 pandemic.
Liu M; Zhao W; Li S; Chen L; Zhou C
Ann Palliat Med; 2022 Apr; 11(4):1231-1240. PubMed ID: 34894701
[TBL] [Abstract][Full Text] [Related]
22. Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US.
Ermer T; Canavan ME; Maduka RC; Li AX; Salazar MC; Kaminski MF; Pichert MD; Zhan PL; Mase V; Kluger H; Boffa DJ
JAMA Netw Open; 2022 Jun; 5(6):e2219535. PubMed ID: 35771575
[TBL] [Abstract][Full Text] [Related]
23. Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global Pandemic.
Kumar S; Chmura S; Robinson C; Lin SH; Gadgeel SM; Donington J; Feliciano J; Stinchcombe TE; Werner-Wasik M; Edelman MJ; Moghanaki D
J Thorac Oncol; 2020 Jul; 15(7):1137-1146. PubMed ID: 32360578
[TBL] [Abstract][Full Text] [Related]
24. A study of the efficacy and toxicity outcomes of extended durvalumab dosing in patients with stage III unresectable non-small cell lung cancer (NSCLC) during the COVID-19 pandemic.
Hanna L; Moffat GT; Hopman W; Gaudreau PO; Fung AS
Cancer Treat Res Commun; 2023; 34():100678. PubMed ID: 36608489
[TBL] [Abstract][Full Text] [Related]
25. Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer.
Shukla NA; Althouse S; Meyer Z; Hanna N; Durm G
Clin Lung Cancer; 2021 Jul; 22(4):274-281. PubMed ID: 33610454
[TBL] [Abstract][Full Text] [Related]
26. Impact of extended interval dosing of immune checkpoint inhibitors in lung cancer patients during the COVID-19 pandemic.
Veron M; Pierret T; Pérol M; Bettega F; Benet J; Denis N; Moro-Sibilot D; Swalduz A; Toffart AC
Respir Med Res; 2023 Jun; 83():101004. PubMed ID: 37037058
[TBL] [Abstract][Full Text] [Related]
27. Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US.
Ganti AK; Klein AB; Cotarla I; Seal B; Chou E
JAMA Oncol; 2021 Dec; 7(12):1824-1832. PubMed ID: 34673888
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario.
Cantini L; Mentrasti G; Russo GL; Signorelli D; Pasello G; Rijavec E; Russano M; Antonuzzo L; Rocco D; Giusti R; Adamo V; Genova C; Tuzi A; Morabito A; Gori S; Verde N; Chiari R; Cortellini A; Cognigni V; Pecci F; Indini A; De Toma A; Zattarin E; Oresti S; Pizzutilo EG; Frega S; Erbetta E; Galletti A; Citarella F; Fancelli S; Caliman E; Della Gravara L; Malapelle U; Filetti M; Piras M; Toscano G; Zullo L; De Tursi M; Di Marino P; D'Emilio V; Cona MS; Guida A; Caglio A; Salerno F; Spinelli G; Bennati C; Morgillo F; Russo A; Dellepiane C; Vallini I; Sforza V; Inno A; Rastelli F; Tassi V; Nicolardi L; Pensieri V; Emili R; Roca E; Migliore A; Galassi T; Rocchi MLB; Berardi R
ESMO Open; 2022 Apr; 7(2):100406. PubMed ID: 35219245
[TBL] [Abstract][Full Text] [Related]
29. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
[TBL] [Abstract][Full Text] [Related]
30. Impact of the COVID-19 pandemic on non-small-cell lung cancer pathologic stage and presentation.
Keogh JAJ; Chhor AD; Begum H; Akhtar-Danesh N; Finley C
Can J Surg; 2022; 65(4):E496-E503. PubMed ID: 35926883
[TBL] [Abstract][Full Text] [Related]
31. Impact of the SARS-CoV-2 pandemic on female breast, colorectal and non-small cell lung cancer incidence, stage and healthcare pathway to diagnosis during 2020 in Wales, UK, using a national cancer clinical record system.
Greene G; Griffiths R; Han J; Akbari A; Jones M; Lyons J; Lyons RA; Rolles M; Torabi F; Warlow J; Morris ERA; Lawler M; Huws DW
Br J Cancer; 2022 Aug; 127(3):558-568. PubMed ID: 35501391
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcomes and resource utilization after surgical resection with curative intent among patients with non-small cell lung cancer treated with adjuvant therapies in a community oncology setting: A real-world retrospective observational study.
Cai B; Fulcher N; Boyd M; Spira A
Thorac Cancer; 2021 Jul; 12(14):2055-2064. PubMed ID: 34028984
[TBL] [Abstract][Full Text] [Related]
33. Italian survey on the clinical management of non-small cell lung cancer patients during the COVID-19 pandemic: A lesson for the second wave.
Bertaglia V; Reale ML; Bironzo P; Palesandro E; Mariniello A; Leone G; Tabbò F; Bungaro M; Audisio M; Rapetti S; Di Stefano RF; Carnio S; Artusio E; Capelletto E; Sperone P; Passiglia F; Novello S
Crit Rev Oncol Hematol; 2021 Jan; 157():103189. PubMed ID: 33341505
[TBL] [Abstract][Full Text] [Related]
34. Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study).
Jung HA; Sun JM; Lee SH; Ahn JS; Ahn MJ; Park K
Lung Cancer; 2020 Aug; 146():112-119. PubMed ID: 32526601
[TBL] [Abstract][Full Text] [Related]
35. Trends in osteoporosis care patterns during the COVID-19 pandemic in Alberta, Canada.
Oliveira T; Brown J; Juby AG; Schneider P; Wani RJ; Packalen M; Avcil S; Li S; Farris M; Graves E; McMullen S; Kendler DL
Arch Osteoporos; 2022 Aug; 17(1):110. PubMed ID: 35920939
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of a National Comprehensive Cancer Network Guidelines-Based Decision Support Tool in Patients With Non-Small Cell Lung Cancer: A Nonrandomized Clinical Trial.
Wu SY; Lazar AA; Gubens MA; Blakely CM; Gottschalk AR; Jablons DM; Jahan TM; Wang VEH; Dunbar TL; Wong ML; Chan JW; Guthrie W; Belkora J; Yom SS
JAMA Netw Open; 2020 Sep; 3(9):e209750. PubMed ID: 32997124
[TBL] [Abstract][Full Text] [Related]
37. Impact of the coronavirus disease 2019 pandemic on primary and metastatic lung cancer treatments in Japan: A nationwide study using an interrupted time series analysis.
Fujita M; Fujisawa T; Suzuki K; Nagashima K; Kasai T; Hashimoto H; Yamaguchi K; Onouchi Y; Sato D; Hata A
Cancer Epidemiol; 2024 Jun; 90():102549. PubMed ID: 38447249
[TBL] [Abstract][Full Text] [Related]
38. Treatment Patterns and Health Resource Utilization Among Patients Diagnosed With Early Stage Resected Non-Small Cell Lung Cancer at US Community Oncology Practices.
Buck PO; Saverno KR; Miller PJ; Arondekar B; Walker MS
Clin Lung Cancer; 2015 Nov; 16(6):486-95. PubMed ID: 25681298
[TBL] [Abstract][Full Text] [Related]
39. A Population-based Study of Treatment Patterns and Survival of Patients With De Novo Stage IV Non-Small Cell Lung Cancer.
Batra A; Yusuf D; Hurry M; Walton RN; Devost N; Farrer C; Cheung WY
Am J Clin Oncol; 2021 Oct; 44(10):512-518. PubMed ID: 34380947
[TBL] [Abstract][Full Text] [Related]
40. Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review.
Ding H; Xin W; Tong Y; Sun J; Xu G; Ye Z; Rao Y
PLoS One; 2020; 15(9):e0238536. PubMed ID: 32877435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
